Trials / Completed
CompletedNCT03447379
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,452 (actual)
- Sponsor
- Gangnam Severance Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting stents (Synergy®)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | P2Y12 antagonist monotherapy | P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) |
| DRUG | Aspirin plus P2Y12 antagonist | DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year |
Timeline
- Start date
- 2017-12-15
- Primary completion
- 2022-03-03
- Completion
- 2022-08-17
- First posted
- 2018-02-27
- Last updated
- 2025-03-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03447379. Inclusion in this directory is not an endorsement.